References
- Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321–333
- Szchzech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med. 2008;16(4):122–126
- Tosini W, Muller P, Prazuck T, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS. 2010;24(15):2375–2380
- Mikhail N, Iskander E, Cope D. Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. Curr Drug Saf. 2009;4(2):121–122
- Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23(10):1603–1614
- Parsonage MJ, Barlow G, Lillie P, et al. Severe myositis on commencement of efavirenz, abacavir and lamivudine, in the absence of lactic acidosis or classical abacavir hypersensitivity. BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.01.2009.1411
- Physicians’ Desk Reference (Viread package insert). 61st ed. Montvale, NJ: Thompson PDR; 2007:1301–1308
- Ho ES, Lin DC, Mendell DB, Chilar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000;11(3):338–393
- Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20(4–7):641–648
- Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50(10):3297–3304
- Servais A, Lechat P, Zahr N, et al. Tubular transporters OAT1 and MRP2 and clearance of adefovir. Nephrol Ther. 2005;1(5):296–300
- Ortiz A, Justo P, Sanz A, et al. Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir Ther. 2005;10(1):185–190
- Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol. 2001;32(7):734–740
- Bendele R, Richardson F. Adefovir nephrotoxicity and mitochondrial DNA depletion. Hum Pathol. 2002;33(5):574
- Van Rompay K, Brignolo L, Meyer D, et al. Biological effects of short term or prolonged administration of 9-[2-(phosponomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004;48(5):1469–1487
- Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta analysis: renal safety of tenofovir disoproxil fumarate in HIV infected patients. Clin Infect Dis. 2010;51(5):496–505
- Zimmerman AE, Pizzoferrato T, Bedford J, et al. Tenofovir associated acute and chronic kidney disease: a case of multiple interactions. Clin Infect Dis. 2006;42(2):283–290
- Joshi MK, Liu HH. Acute rhabdomyolysis and renal failure in HIV-infected patients: risk factors, presentation, and pathophysiology. AIDS Patient Care STDs. 2000;14(10):541–548
- Younger DS, Hays AP, Uncini A, et al. Recurrent myoglobinuria and HIV seropositivity: incidental or pathogenic association? Muscle Nerve. 1989;12(10):842–843
- Dori L, Buonomni AR, Viscione M, et al. A case of rhabdomyolysis associated with raltegravir use. AIDS. 2010;24(3):473–475
- Zembower TR, Gerzenshtein L, Coleman K, Palella FJ Jr. Severe rhabdomyolysis associated with raltegravir use. AIDS. 2008;22(11):1382–1384
- Callens S, De Roo A, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect. 2003;47(3):262–263
- Shere-Wolfe KD, Verley JR. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir. Clin Infect Dis. 2002;35(9):1137